Table 2 Comparison of prognostic/predictive models.

IPI

Age >60 years (1);

Increased LDH (1);

PS ≥ 2 (1);

Stage-III/IV (1);

Extra-nodal disease ≥2 (1)

Low-risk (0–1)

Intermediate low-risk (2)

Intermediate high-risk (3)

High-risk (≥4)

Development

–

0.62

0.61

KPI

B-symptoms (1);

Stage-III/IV (1);

Increased LDH (1);

Regional lymph node involvement (1)

Group 1 (0)

Group 2 (1)

Group 3 (2)

Group 4 (≥3)

Development

Validation

0.64

0.68

PINK

Age >60 years (1);

Stage-III/IV (1);

Distant lymph node involvement (1);

Non-nasal disease (1)

Low-risk (0)

Intermediate-risk (1)

High-risk (≥2)

–

Development and validation

0.61

0.63

NRI

Age >60 years (1);

Stage-II (1);

Stage-III/IV (2);

PS ≥ 2 (1);

Increased LDH (1);

With PTI (1)

Low-risk (0)

Intermediate low-risk (1)

Intermediate high-risk (2)

High-risk (3)

Very high-risk (≥4)

Development

Validation

0.70

0.72